To reduce the risk of food allergies, infants should have eggs and peanuts incorporated into their diet within their first year of life.
This includes children at high risk, according to guidelines published by the Australasian Society of Clinical Immunology and Allergy (ASCIA) and summarised in the Medical Journal of Australia.
The guidelines, published in 2016 with additional guidance published in 2017 and 2018, included recommendations to introduce solid foods at around six months of age and peanut and egg before 12 months, but not before four months. The guidelines no longer recommend the use of hydrolysed formula for the prevention of allergic diseases.
Allergy Therapeutics (LON:AGY) is an international commercial biotechnology group focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.